GSK and Vir Report Results of Sotrovimab in P-III COMET-ICE Trial for High-Risk Adult Patients with Mild-To-Moderate COVID-19
Shots:
- The P-III COMET-ICE trial involves assessing sotrovimab vs PBO in 1057 patients with mild-to-moderate COVID-19
- The trial meets its 1EPs i.e. a 79% reduction in hospitalization for >24hrs. or death due to any cause @29day. Additionally- NIH update its treatment guidelines to recommend the use of therapy for non-hospitalized patients with COVID-19 who are at high risk of clinical progression
- The companies plan to submit the results to a peer-reviewed journal for publication & BLA to FDA in H2’21 while the therapy is continuing to advance with COMET clinical development program to provide clinical evidence from several studies in 2022
Ref: GSK | Image: GSK
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com